Innovative drug

Liu Yongjun’s experience in the commercialization of innovative drugs and his connections with multinational pharmaceutical companies are urgently needed for CSPC Pharmaceutical’s ongoing transformation.

CSPC Pharma taps R&D superstar in quest for new breakout drugs

Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
1093.HK
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
9926.HK
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs.

Profit setback for Simcere Pharma in novel drugs quest

The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
2096.HK
Gracell Biotechnologies announced Tuesday that its shareholders approved the company’s sale to AstraZeneca at an extraordinary general meeting on Feb. 19.

FAST NEWS: Gracell shareholders approve merger with AstraZeneca

The latest: Gracell Biotechnologies Inc. (GRCL.US) announced Tuesday that its shareholders approved the company’s sale to AstraZeneca (AZN.L) at an extraordinary general meeting on Feb. 19. Looking up: Gracell’s merger with…
GRCL.US

Recent Articles

RELATED ARTICLES

  1. This biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug.
    Innovent Bio hopes for plus-sized profits from obesity drug
    1801.HK
  2. CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  3. Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  4. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva